Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Recruiting · NCT06663111 · Observational (researchers observe without assigning treatment) · Lead sponsor: Haukeland University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Blood samples for PK
What this trial is about
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Included in OVERLORD-MS (NCT04578639)
- Willing to attend laboratory for blood sample collection at scheduled time points
Exclusion criteria
- \* Not willing to attend laboratory for blood sample collection at scheduled time points
Where it is running
1 location listed.
- Haukeland University Hospital, Deparment of medical biochemistry and pharmacology - Bergen, Vestland, Norway